After nine hours of deliberation Thursday, a special panel of the U.S. Food and Drug Administration approved for emergency use a coronavirus vaccine developed by U.S. pharmaceutical giant Pfizer and Germany’s BioNTech. The decision was made as the U.S. continues to confirm record numbers of coronavirus cases. As of Thursday evening, the U.S. had recorded 15.5 million cases and more than 291,000 deaths, according to Johns Hopkins University data. Of the 22 people on the special panel of the Food and Drug Administration (FDA), 17 voted yes, four voted no and one abstained on the question: “Based on the totality of scientific evidence available, do the benefits of the Pfizer/BioNTech COVID-19 vaccine outweigh its risks for use in individuals 16 years of age and older?” With the recommendation of the emergency use authorization by the Vaccines and Related Biological Products Advisory Committee, the FDA will likely give its final consent as early as …